MIRATI THERAPEUTICS INC (MRTX)
US60468T1051 - Common Stock
MRTX gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 565 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for MRTX as it has an excellent financial health rating, but there are worries on the profitability. MRTX is valued quite expensively, but it does show have an excellent growth rating.
1. Profitability
1.1 Basic Checks
In the past year MRTX has reported negative net income.
In the past year MRTX has reported a negative cash flow from operations.
MRTX had negative earnings in each of the past 5 years.
MRTX had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
MRTX's Return On Assets of -64.25% is on the low side compared to the rest of the industry. MRTX is outperformed by 64.25% of its industry peers.
MRTX's Return On Equity of -76.69% is in line compared to the rest of the industry. MRTX outperforms 50.25% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -64.25% | ||
| ROE | -76.69% | ||
| ROIC | N/A |
ROA(3y)-40.82%
ROA(5y)-42.98%
ROE(3y)-47.43%
ROE(5y)-49.38%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
MRTX has a better Gross Margin (88.50%) than 90.56% of its industry peers.
The Profit Margin and Operating Margin are not available for MRTX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 88.5% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
MRTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, MRTX has more shares outstanding
The number of shares outstanding for MRTX has been increased compared to 5 years ago.
MRTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 8.55 indicates that MRTX is not in any danger for bankruptcy at the moment.
MRTX has a better Altman-Z score (8.55) than 83.64% of its industry peers.
There is no outstanding debt for MRTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 8.55 |
ROIC/WACCN/A
WACC10.5%
2.3 Liquidity
MRTX has a Current Ratio of 7.54. This indicates that MRTX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 7.54, MRTX is in the better half of the industry, outperforming 67.79% of the companies in the same industry.
A Quick Ratio of 7.39 indicates that MRTX has no problem at all paying its short term obligations.
The Quick ratio of MRTX (7.39) is better than 67.28% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.54 | ||
| Quick Ratio | 7.39 |
3. Growth
3.1 Past
MRTX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 8.74%, which is quite good.
The Revenue has grown by 223.64% in the past year. This is a very strong growth!
MRTX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 55.01% yearly.
EPS 1Y (TTM)8.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%19.42%
Revenue 1Y (TTM)223.64%
Revenue growth 3Y55.01%
Revenue growth 5YN/A
Sales Q2Q%202.03%
3.2 Future
MRTX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.99% yearly.
Based on estimates for the next years, MRTX will show a very strong growth in Revenue. The Revenue will grow by 126.18% on average per year.
EPS Next Y14.07%
EPS Next 2Y13.75%
EPS Next 3Y12.15%
EPS Next 5Y12.99%
Revenue Next Year406.04%
Revenue Next 2Y283.08%
Revenue Next 3Y198%
Revenue Next 5Y126.18%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for MRTX. In the last year negative earnings were reported.
Also next year MRTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as MRTX's earnings are expected to grow with 12.15% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y13.75%
EPS Next 3Y12.15%
5. Dividend
5.1 Amount
MRTX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
MIRATI THERAPEUTICS INC
NASDAQ:MRTX (1/22/2024, 8:00:02 PM)
After market: 58.99 +0.29 (+0.49%)58.7
-0.1 (-0.17%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners4.62%
Inst Owner Change-6.95%
Ins Owners10.58%
Ins Owner Change0%
Market Cap4.12B
Analysts69.09
Price Target62.42 (6.34%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)10.01%
Min EPS beat(2)6.02%
Max EPS beat(2)14.01%
EPS beat(4)4
Avg EPS beat(4)8.85%
Min EPS beat(4)3.16%
Max EPS beat(4)14.01%
EPS beat(8)7
Avg EPS beat(8)5.22%
EPS beat(12)9
Avg EPS beat(12)3.61%
EPS beat(16)11
Avg EPS beat(16)0.87%
Revenue beat(2)0
Avg Revenue beat(2)-7.1%
Min Revenue beat(2)-13.55%
Max Revenue beat(2)-0.65%
Revenue beat(4)1
Avg Revenue beat(4)-6.74%
Min Revenue beat(4)-59.88%
Max Revenue beat(4)47.11%
Revenue beat(8)4
Avg Revenue beat(8)247.34%
Revenue beat(12)6
Avg Revenue beat(12)238.35%
Revenue beat(16)8
Avg Revenue beat(16)201.02%
PT rev (1m)0.84%
PT rev (3m)12.84%
EPS NQ rev (1m)-0.83%
EPS NQ rev (3m)2.99%
EPS NY rev (1m)0.29%
EPS NY rev (3m)4.82%
Revenue NQ rev (1m)-0.7%
Revenue NQ rev (3m)2.49%
Revenue NY rev (1m)-2.26%
Revenue NY rev (3m)-3.77%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 107.82 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 4.35 | ||
| P/tB | 4.42 | ||
| EV/EBITDA | N/A |
EPS(TTM)-12.22
EYN/A
EPS(NY)-9.31
Fwd EYN/A
FCF(TTM)-8.5
FCFYN/A
OCF(TTM)-8.47
OCFYN/A
SpS0.54
BVpS13.49
TBVpS13.29
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -64.25% | ||
| ROE | -76.69% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 88.5% | ||
| FCFM | N/A |
ROA(3y)-40.82%
ROA(5y)-42.98%
ROE(3y)-47.43%
ROE(5y)-49.38%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.03
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 43.91% | ||
| Cap/Sales | 4.82% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 7.54 | ||
| Quick Ratio | 7.39 | ||
| Altman-Z | 8.55 |
F-Score4
WACC10.5%
ROIC/WACCN/A
Cap/Depr(3y)466.3%
Cap/Depr(5y)417.11%
Cap/Sales(3y)28.4%
Cap/Sales(5y)26.51%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)8.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%19.42%
EPS Next Y14.07%
EPS Next 2Y13.75%
EPS Next 3Y12.15%
EPS Next 5Y12.99%
Revenue 1Y (TTM)223.64%
Revenue growth 3Y55.01%
Revenue growth 5YN/A
Sales Q2Q%202.03%
Revenue Next Year406.04%
Revenue Next 2Y283.08%
Revenue Next 3Y198%
Revenue Next 5Y126.18%
EBIT growth 1Y-2.67%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-91.48%
EBIT Next 3Y-11.53%
EBIT Next 5YN/A
FCF growth 1Y-77.42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-81.55%
OCF growth 3YN/A
OCF growth 5YN/A